Clinical and genetic markers associated with tuberculosis, HIV-1 infection, and TB/HIV-immune reconstitution inflammatory syndrome outcomes.
Brazil
Coinfection
/ drug therapy
Female
Follow-Up Studies
Gene Frequency
/ genetics
Genetic Markers
Genotype
HIV Infections
/ complications
HIV-1
HLA-B Antigens
/ genetics
HLA-C Antigens
/ genetics
Humans
Immune Reconstitution Inflammatory Syndrome
/ etiology
Male
Receptors, KIR
/ genetics
Sex Factors
Tuberculosis
/ complications
HIV-1
HLA-B genes
HLA-C genes
Immune Reconstitution Inflammatory Syndrome
KIR genes
Tuberculosis
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
20 Jan 2020
20 Jan 2020
Historique:
received:
13
03
2019
accepted:
09
01
2020
entrez:
22
1
2020
pubmed:
22
1
2020
medline:
9
4
2020
Statut:
epublish
Résumé
Tuberculosis (TB) and AIDS are the leading causes of infectious disease death worldwide. In some TB-HIV co-infected individuals treated for both diseases simultaneously, a pathological inflammatory reaction termed immune reconstitution inflammatory syndrome (IRIS) may occur. The risk factors for IRIS are not fully defined. We investigated the association of HLA-B, HLA-C, and KIR genotypes with TB, HIV-1 infection, and IRIS onset. Patients were divided into four groups: Group 1- TB+/HIV+ (n = 88; 11 of them with IRIS), Group 2- HIV+ (n = 24), Group 3- TB+ (n = 24) and Group 4- healthy volunteers (n = 26). Patients were followed up at INI/FIOCRUZ and HGNI (Rio de Janeiro/Brazil) from 2006 to 2016. The HLA-B and HLA-C loci were typed using SBT, NGS, and KIR genes by PCR-SSP. Unconditional logistic regression models were performed for Protection/risk estimation. Among the individuals with TB as the outcome, KIR2DS2 was associated with increased risk for TB onset (aOR = 2.39, P = 0.04), whereas HLA-B*08 and female gender were associated with protection against TB onset (aOR = 0.23, P = 0.03, and aOR = 0.33, P = 0.01, respectively). Not carrying KIR2DL3 (aOR = 0.18, P = 0.03) and carrying HLA-C*07 (aOR = 0.32, P = 0.04) were associated with protection against TB onset among HIV-infected patients. An increased risk for IRIS onset was associated with having a CD8 count ≤500 cells/mm
Sections du résumé
BACKGROUND
BACKGROUND
Tuberculosis (TB) and AIDS are the leading causes of infectious disease death worldwide. In some TB-HIV co-infected individuals treated for both diseases simultaneously, a pathological inflammatory reaction termed immune reconstitution inflammatory syndrome (IRIS) may occur. The risk factors for IRIS are not fully defined. We investigated the association of HLA-B, HLA-C, and KIR genotypes with TB, HIV-1 infection, and IRIS onset.
METHODS
METHODS
Patients were divided into four groups: Group 1- TB+/HIV+ (n = 88; 11 of them with IRIS), Group 2- HIV+ (n = 24), Group 3- TB+ (n = 24) and Group 4- healthy volunteers (n = 26). Patients were followed up at INI/FIOCRUZ and HGNI (Rio de Janeiro/Brazil) from 2006 to 2016. The HLA-B and HLA-C loci were typed using SBT, NGS, and KIR genes by PCR-SSP. Unconditional logistic regression models were performed for Protection/risk estimation.
RESULTS
RESULTS
Among the individuals with TB as the outcome, KIR2DS2 was associated with increased risk for TB onset (aOR = 2.39, P = 0.04), whereas HLA-B*08 and female gender were associated with protection against TB onset (aOR = 0.23, P = 0.03, and aOR = 0.33, P = 0.01, respectively). Not carrying KIR2DL3 (aOR = 0.18, P = 0.03) and carrying HLA-C*07 (aOR = 0.32, P = 0.04) were associated with protection against TB onset among HIV-infected patients. An increased risk for IRIS onset was associated with having a CD8 count ≤500 cells/mm
Identifiants
pubmed: 31959123
doi: 10.1186/s12879-020-4786-5
pii: 10.1186/s12879-020-4786-5
pmc: PMC6971853
doi:
Substances chimiques
Genetic Markers
0
HLA-B Antigens
0
HLA-C Antigens
0
KIR2DS2 protein, human
0
Receptors, KIR
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
59Subventions
Organisme : Conselho Nacional de Desenvolvimento Científico e Tecnológico
ID : 404573/2012-6
Organisme : France Recherche Nord & Sud Sida-HIV Hépatites - ANRS
ID : ANRS12274
Références
Blood. 2010 Nov 11;116(19):3818-27
pubmed: 20660788
J Infect Dis. 2010 Dec 1;202(11):1728-37
pubmed: 20977362
J Ophthalmol. 2018 Sep 02;2018:3830104
pubmed: 30245869
Semin Immunol. 2008 Dec;20(6):343-52
pubmed: 18635379
Eur Respir Rev. 2017 Jan 3;26(143):
pubmed: 28049128
Int J Tuberc Lung Dis. 2011 Dec;15(12):1688-91
pubmed: 22118180
Immunol Rev. 2013 Jul;254(1):245-64
pubmed: 23772624
Hum Immunol. 2013 Jan;74(1):85-92
pubmed: 23073291
Hum Immunol. 2016 Oct;77(10):854-860
pubmed: 27346697
Clin Infect Dis. 2006 Jun 1;42(11):1639-46
pubmed: 16652323
Infection. 2017 Jun;45(3):283-290
pubmed: 27866367
AIDS. 2010 Jul 31;24(12):1835-40
pubmed: 20588164
J Acquir Immune Defic Syndr. 2014 Apr 1;65(4):423-8
pubmed: 24226057
Nucleic Acids Res. 2013 Jan;41(Database issue):D1234-40
pubmed: 23180793
Semin Immunopathol. 2016 Mar;38(2):185-98
pubmed: 26423994
Infect Genet Evol. 2006 Nov;6(6):436-9
pubmed: 16563877
Curr Genet Med Rep. 2017 Dec;5(4):149-166
pubmed: 29805915
Tissue Antigens. 2009 Nov;74(5):373-85
pubmed: 19765261
Int J Immunogenet. 2010 Apr;37(2):83-9
pubmed: 20082646
BMC Infect Dis. 2016 Sep 27;16(1):518
pubmed: 27677424
Curr Opin HIV AIDS. 2008 Jul;3(4):468-76
pubmed: 19373007
J Exp Med. 1996 Sep 1;184(3):913-22
pubmed: 9064351
Enferm Infecc Microbiol Clin. 2014 Nov;32(9):565-9
pubmed: 24332713
Tuberculosis (Edinb). 2015 Dec;95(6):817-821
pubmed: 26542219
Nature. 2004 Dec 9;432(7018):769-75
pubmed: 15592417
J Infect. 2006 Dec;53(6):357-63
pubmed: 16487593
Tissue Antigens. 2006 Nov;68(5):386-9
pubmed: 17092251
J Immunol. 2016 May 15;196(10):4052-63
pubmed: 27076678
Annu Rev Med. 2003;54:535-51
pubmed: 12525683
J Virol. 2015 Jan;89(1):97-109
pubmed: 25320293
Hum Immunol. 2016 Jan;77(1):41-46
pubmed: 26472014
Hum Reprod. 2011 Feb;26(2):491-7
pubmed: 21159685
Cell Microbiol. 2012 Nov;14(11):1734-44
pubmed: 22788220
EBioMedicine. 2016 Feb 06;4:9-10
pubmed: 26981561
Clin Infect Dis. 2012 Oct;55(7):1004-11
pubmed: 22715179
Clin Infect Dis. 2005 Dec 15;41(12):1783-6
pubmed: 16288404
Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):12000-4
pubmed: 8265660
Hum Immunol. 2017 Oct;78(10):602-609
pubmed: 28803786
PLoS One. 2015 Jul 24;10(7):e0133924
pubmed: 26208109
Int J Immunogenet. 2015 Feb;42(1):19-25
pubmed: 25418108
AIDS. 2005 Mar 4;19(4):399-406
pubmed: 15750393
Curr Opin Infect Dis. 2016 Feb;29(1):10-22
pubmed: 26658650
Braz J Infect Dis. 2008 Aug;12(4):278-80
pubmed: 19030725
Dis Markers. 2013;34(6):445-9
pubmed: 23594560
AIDS. 2015 Feb 20;29(4):421-31
pubmed: 25565499
Parasite Immunol. 2004 Jun-Jul;26(6-7):247-64
pubmed: 15541029
Mol Immunol. 2015 Dec;68(2 Pt A):89-93
pubmed: 26239417
PLoS One. 2013 Jun 19;8(6):e66095
pubmed: 23840403
Int Immunol. 2009 Jul;21(7):779-91
pubmed: 19461127
Lancet Infect Dis. 2010 Apr;10(4):251-61
pubmed: 20334848
Ann Intern Med. 2012 Sep 4;157(5):313-24
pubmed: 22944873
Immunol Rev. 2008 Aug;224:70-84
pubmed: 18759921
Immunobiology. 2014 Jan;219(1):37-44
pubmed: 23958034
Indian J Biochem Biophys. 2003 Oct;40(5):291-9
pubmed: 22900322
Nat Commun. 2015 Sep 24;6:8451
pubmed: 26399326
Arch Immunol Ther Exp (Warsz). 2011 Jun;59(3):203-13
pubmed: 21442309
BMC Genet. 2015 Jun 16;16:63
pubmed: 26077983
QJM. 1996 Mar;89(3):177-85
pubmed: 8731561
Front Immunol. 2019 Aug 13;10:1800
pubmed: 31456797
J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):309-18
pubmed: 21826013
Immunity. 1997 Dec;7(6):753-63
pubmed: 9430221
Rev Bras Reumatol. 2011 Jul-Aug;51(4):351-6, 362-4
pubmed: 21779711
PLoS One. 2014 Oct 17;9(10):e110480
pubmed: 25330014
PLoS One. 2019 Jun 6;14(6):e0217014
pubmed: 31170171
Future Microbiol. 2015;10(6):1077-99
pubmed: 26059627
Curr HIV/AIDS Rep. 2014 Sep;11(3):223-32
pubmed: 24950732
J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):640-1
pubmed: 19628981
Stat Med. 1997 Apr 15;16(7):791-801
pubmed: 9131766
J Infect Dis. 2017 Nov 27;216(9):1159-1163
pubmed: 29040604
Immunogenetics. 2018 Aug;70(8):511-522
pubmed: 29696367
PLoS One. 2013 Jul 05;8(7):e67780
pubmed: 23861805
AIDS Res Ther. 2007 May 08;4:9
pubmed: 17488505
AIDS. 2013 Oct 23;27(16):2577-86
pubmed: 24096631
Int Arch Allergy Immunol. 2017;172(3):150-160
pubmed: 28380482
Sci Rep. 2016 Feb 26;6:22060
pubmed: 26916387
Blood. 2012 Apr 5;119(14):3315-20
pubmed: 22343919
AIDS. 2013 Jul 17;27(11):1725-34
pubmed: 23807270
Braz J Infect Dis. 2007 Oct;11(5):462-5
pubmed: 17962870
Hum Immunol. 2010 Jul;71(7):697-701
pubmed: 20438789
BMC Infect Dis. 2017 Sep 6;17(1):606
pubmed: 28874142
Genes Immun. 2014 Apr;15(4):256-62
pubmed: 24718028
Immunogenetics. 2012 Feb;64(2):143-52
pubmed: 21850526
Nature. 2011 Aug 03;476(7358):96-100
pubmed: 21814282
J Immunol. 2009 Sep 15;183(6):3915-23
pubmed: 19726768
Hum Immunol. 2008 Dec;69(12):872-6
pubmed: 18848853
PLoS One. 2011 Feb 08;6(2):e16541
pubmed: 21346814
HIV AIDS (Auckl). 2015 Feb 12;7:49-64
pubmed: 25709503
Semin Diagn Pathol. 2017 Jul;34(4):340-351
pubmed: 28552210
Scand J Immunol. 2008 Jul;68(1):92-102
pubmed: 18484953
Immunol Cell Biol. 2011 Feb;89(2):216-24
pubmed: 20567250